Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia

Chronic eosinophilic pneumonia (CEP) is an eosinophilic inflammatory disease of unknown etiology, and oral corticosteroid (OCS) is commonly used for its treatment. Approximately half of CEP cases relapse secondary to reduction or termination of OCS. A 43-year-old woman visited our hospital because o...

Descripción completa

Detalles Bibliográficos
Autores principales: Izumo, Takehiro, Kuse, Naoyuki, Awano, Nobuyasu, Tone, Mari, Jo, Tatsunori, Yoshimura, Hanako, Minami, Jonsu, Takada, Kohei, Muto, Yutaka, Fujimoto, Kazushi, Inomata, Minoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193122/
https://www.ncbi.nlm.nih.gov/pubmed/32373456
http://dx.doi.org/10.1016/j.rmcr.2020.101062
_version_ 1783528131666116608
author Izumo, Takehiro
Kuse, Naoyuki
Awano, Nobuyasu
Tone, Mari
Jo, Tatsunori
Yoshimura, Hanako
Minami, Jonsu
Takada, Kohei
Muto, Yutaka
Fujimoto, Kazushi
Inomata, Minoru
author_facet Izumo, Takehiro
Kuse, Naoyuki
Awano, Nobuyasu
Tone, Mari
Jo, Tatsunori
Yoshimura, Hanako
Minami, Jonsu
Takada, Kohei
Muto, Yutaka
Fujimoto, Kazushi
Inomata, Minoru
author_sort Izumo, Takehiro
collection PubMed
description Chronic eosinophilic pneumonia (CEP) is an eosinophilic inflammatory disease of unknown etiology, and oral corticosteroid (OCS) is commonly used for its treatment. Approximately half of CEP cases relapse secondary to reduction or termination of OCS. A 43-year-old woman visited our hospital because of a chronic cough and abnormal chest X-ray findings. She was diagnosed with CEP because of marked eosinophilia, as well as eosinophilic infiltrates in cryobiopsy samples. After initiation of OCS treatment, her symptoms disappeared with a decrease in peripheral blood eosinophil counts and the amelioration of abnormal infiltrative shadows on chest X-ray. However, symptoms reappeared after OCS termination, including a recurrence of eosinophilia and appearance of fresh abnormal shadows on chest X-ray. Because she refused readministration of OCS because of side effects such as appetite enhancement and moon face in last treatment course, we administered her a single dose of benralizumab. Her symptoms and peripheral eosinophil counts were markedly ameliorated 1 week after benralizumab administration. The marked amelioration in abnormal shadows on chest X-ray were maintained 2 weeks after benralizumab administration. She had no relapse of CEP for almost 6 months after benralizumab administration. Our experience with this case suggests that a single dose of benralizumab may be a treatment option for relapsed CEP cases or those with side effects of long-term OCS therapy.
format Online
Article
Text
id pubmed-7193122
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-71931222020-05-05 Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia Izumo, Takehiro Kuse, Naoyuki Awano, Nobuyasu Tone, Mari Jo, Tatsunori Yoshimura, Hanako Minami, Jonsu Takada, Kohei Muto, Yutaka Fujimoto, Kazushi Inomata, Minoru Respir Med Case Rep Case Report Chronic eosinophilic pneumonia (CEP) is an eosinophilic inflammatory disease of unknown etiology, and oral corticosteroid (OCS) is commonly used for its treatment. Approximately half of CEP cases relapse secondary to reduction or termination of OCS. A 43-year-old woman visited our hospital because of a chronic cough and abnormal chest X-ray findings. She was diagnosed with CEP because of marked eosinophilia, as well as eosinophilic infiltrates in cryobiopsy samples. After initiation of OCS treatment, her symptoms disappeared with a decrease in peripheral blood eosinophil counts and the amelioration of abnormal infiltrative shadows on chest X-ray. However, symptoms reappeared after OCS termination, including a recurrence of eosinophilia and appearance of fresh abnormal shadows on chest X-ray. Because she refused readministration of OCS because of side effects such as appetite enhancement and moon face in last treatment course, we administered her a single dose of benralizumab. Her symptoms and peripheral eosinophil counts were markedly ameliorated 1 week after benralizumab administration. The marked amelioration in abnormal shadows on chest X-ray were maintained 2 weeks after benralizumab administration. She had no relapse of CEP for almost 6 months after benralizumab administration. Our experience with this case suggests that a single dose of benralizumab may be a treatment option for relapsed CEP cases or those with side effects of long-term OCS therapy. Elsevier 2020-04-22 /pmc/articles/PMC7193122/ /pubmed/32373456 http://dx.doi.org/10.1016/j.rmcr.2020.101062 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Izumo, Takehiro
Kuse, Naoyuki
Awano, Nobuyasu
Tone, Mari
Jo, Tatsunori
Yoshimura, Hanako
Minami, Jonsu
Takada, Kohei
Muto, Yutaka
Fujimoto, Kazushi
Inomata, Minoru
Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia
title Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia
title_full Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia
title_fullStr Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia
title_full_unstemmed Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia
title_short Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia
title_sort rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193122/
https://www.ncbi.nlm.nih.gov/pubmed/32373456
http://dx.doi.org/10.1016/j.rmcr.2020.101062
work_keys_str_mv AT izumotakehiro rapidandsustainedeffectsofasingledoseofbenralizumabonchroniceosinophilicpneumonia
AT kusenaoyuki rapidandsustainedeffectsofasingledoseofbenralizumabonchroniceosinophilicpneumonia
AT awanonobuyasu rapidandsustainedeffectsofasingledoseofbenralizumabonchroniceosinophilicpneumonia
AT tonemari rapidandsustainedeffectsofasingledoseofbenralizumabonchroniceosinophilicpneumonia
AT jotatsunori rapidandsustainedeffectsofasingledoseofbenralizumabonchroniceosinophilicpneumonia
AT yoshimurahanako rapidandsustainedeffectsofasingledoseofbenralizumabonchroniceosinophilicpneumonia
AT minamijonsu rapidandsustainedeffectsofasingledoseofbenralizumabonchroniceosinophilicpneumonia
AT takadakohei rapidandsustainedeffectsofasingledoseofbenralizumabonchroniceosinophilicpneumonia
AT mutoyutaka rapidandsustainedeffectsofasingledoseofbenralizumabonchroniceosinophilicpneumonia
AT fujimotokazushi rapidandsustainedeffectsofasingledoseofbenralizumabonchroniceosinophilicpneumonia
AT inomataminoru rapidandsustainedeffectsofasingledoseofbenralizumabonchroniceosinophilicpneumonia